$BSX · BOSTON SCIENTIFIC CORP

Boston Scientific filed an 8-K announcing the promotion of Joe Fitzgerald to EVP and Chief Operating Officer effective January 1, 2027, and a concurrent reorganization into three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg. Fitzgerald, a 36-year company veteran, will receive a $1.05M base salary, 110% bonus target, and $7M in annual equity awards. Three segment presidents — Lance Bates, Nick Spadea-Anello, and Stephen Morse — will report to Fitzgerald.

Markets closed — no regular-session reaction yet. Extended-hours last trade at $42.24 (+0.12% vs regular close), suggesting minimal immediate price sensitivity to the leadership and restructuring announcement.

A COO appointment paired with a segment restructure signals BSX is scaling its operating model to match portfolio breadth, with the Penumbra integration as a near-term catalyst.

Large-cap medtech peers (MDT, ABT, SYK) have similarly adopted segment-based operating models to improve agility as portfolios expand; BSX's move formalizes a structure that mirrors this industry trend.

Execution risk from simultaneous COO transition and segment restructuring; the filing notes forward-looking risks including integration of the Penumbra acquisition and potential disruption from the new operating model.